A FATAL CASE OF BILATERAL INTERSTITIAL PNEUMONIA (BLIP): INTERFERON ALPHA 2 A INDUCED.
Â Adult T-cell leukemia/lymphoma (ATLL) is a rare lymph proliferative disorder of mature CD4 T-cells caused by the human T-lymph tropic type 1 (HTLV 1) of retrovirus family. Combination of zidovudine and interferon Alfa combination is one of most commonly used regimen. Many drugs are implicated in causing interstitial lung disease. Hence, we report a case of interferon Alfa-induced bilateral interstitial pneumonia in a 32-year-old female patient diagnosed with ATLL with HTLV 1 positivity.
2. Gill PS, Harrington W Jr, Kaplan MH, Ribeiro RC, Bennett JM, Liebman HA, et al. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med 1995;332(26):1744-8.
3. Paul AM, Antony A, Sruti NU, Bameed H. A case report on ayurvedic medicine (red mercuric sulphate) induced bronchiolitis obliterans organizing pneumonia (boop) in sero positive rheumatoid patient. Int J Pharm Pharm Sci 2015;7(11):399-401.
4. Coultas DB, Zumwalt RE, Black WC, Sobonya RE. The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med 1994;150(4):967-72.
5. Khader A, Shaan M, Balakrishnan S, Ambooken B, Muhammed K, Rajan U. Multifaceted adult T-cell leukemia/lymphoma in India: A case series. Indian J Dermatol 2015;60(1):103.
6. Furman PA, Fyfe JA, St Clair MH, Weinhold K, Rideout JL, Freeman GA, et al. Phosphorylation of 3â€™-azido-3â€™-deoxythymidine and selective interaction of the 5â€™-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci U S A 1986;83(21):8333-7.
7. Friedman RL, Manly SP, McMahon M, Kerr IM, Stark GR. Transcriptional and posttranscriptional regulation of interferon-induced gene expression in human cells. Cell 1984;38(3):745-55.
8. Schwaiblmair M, Behr W, Haeckel T, MÃ¤rkl B, Foerg W, Berghaus T. Drug induced interstitial lung disease. Open Respir Med J 2012;6:63-74.
9. Solsky J, Liu J, Peng M, Schaerer M, Tietz A. Rate of interstitial pneumonitis among hepatitis virus C-infected patients treated with pegylated interferon. J Hepatol 2009;50 Suppl 1:S238.
10. Kumar KS, Russo MW, Borczuk AC, Brown M, Esposito SP, Lobritto SJ, et al. Significant pulmonary toxicity associated with interferon and ribavirin therapy for hepatitis C. Am J Gastroenterol 2002;97(9):2432-40.
11. Tilg H. New insights into the mechanisms of interferon alfa: An immunoregulatory and anti-inflammatory cytokine. Gastroenterology 1997;112(3):1017-21.
12. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30(2):239-45.
13. Raut A, Pawar A, Pankaj M, Srivastava P, Mishra A. Clinical pattern and severity of cutaneous adverse drug reactions. Int J Pharm Pharm Sci 2013;5(2):612-6.
14. Schumock GT, Thornton JP. Focusing on the preventability of adverse drug reactions. Hosp Pharm 1992;27(6):538.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.